Immunszupprimált betegek multiplex bőrdaganatainak elektrokemoterápiás kezelése [Electrochemotherapy for multiple cutaneous tumors in immunosuppressed patients]

Introduction: The risk of cutaneous malignancies is significantly higher in immunosuppressed patients compared to the general population. These high-risk skin tumors tend to be aggressive, multiplex, rapidly growing lesions. It is common to see local recurrence after surgical excision. Multiplex tum...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Rózsa Petra
Ágoston Dóra
Szederkényi Edit
Ócsai Henriette
Baltás Eszter
Vass Gábor
Kemény Lajos
Oláh Judit
Kis Erika
Dokumentumtípus: Cikk
Megjelent: 2023
Sorozat:ORVOSI HETILAP 164 No. 37
Tárgyszavak:
doi:10.1556/650.2023.32852

mtmt:34340896
Online Access:http://publicatio.bibl.u-szeged.hu/28942
Leíró adatok
Tartalmi kivonat:Introduction: The risk of cutaneous malignancies is significantly higher in immunosuppressed patients compared to the general population. These high-risk skin tumors tend to be aggressive, multiplex, rapidly growing lesions. It is common to see local recurrence after surgical excision. Multiplex tumors are difficult to treat, especially in the head/ neck region.Objective: Amongst the standard treatment options, electrochemotherapy can be a suitable option. Our aim was to evaluate the efficacy of electrochemotherapy in immunocompromised patients.Method: In 9 immunosuppressed patients, 118 (average: 13, n = 5-27) non-melanoma skin tumors were treated with electrochemotherapy with intravenous administration of bleomycin, according to the ESOPE criteria.Results: The median follow-up was 15 months. 6 months after the treatment, the objective response rate was 96%. We observed complete response in 88%, partial response in 8% and progressive disease in 2% of the treated lesions. In 2%, the response was not evaluable.Conclusion: In immunocompromised patients, electrochemotherapy is an effective and safe therapeutic option for non-melanoma skin tumors. In order to provide more ideal management for this special sub-group, prevention, multidisciplinary approach and optimized immunosuppressive therapy is essential.
Terjedelem/Fizikai jellemzők:1462-1468
ISSN:0030-6002